



## Drugs used for peptic ulcer

### Color Guide

Slides = Black  
Females notes = Green  
female slides= purple  
Males slides= Blue  
Explanation=Orange

**This lecture was done by:**  
Heba alsharif & Alanoud alhoqail

**And was reviewed by:**  
Ali Saeed Alrawdhan

## Objectives:


- **Understand the key points of pathophysiology of the peptic ulcer disease**
- **Enumerate various classes of drugs used in peptic ulcer disease**
- **Correlate actions of anti-ulcer drugs with pathophysiology of the disease.**
- **Understand the mechanisms of action, routes of administration and adverse of drugs used in peptic ulcer disease.**
- **Understand the rationale of combination triple & quadruple therapy for H. pylori infected ulcers**
- **Identify potential adverse drug interactions of anti-ulcer drugs.**

Peptic ulcer disease (PUD)

A localized lesion of the mucous membrane of the :


- stomach (gastric ulcer)
  - duodenum (duodenal ulcer)
- typically extending through the muscularis mucosa.

Ulceration in esophagus due to regurgitation of the gastric content



Pathophysiology

•Is imbalance between:




•Prostaglandin is very protective for the mucosal layer special subtype E,I .

•However, nowadays, it seems that H. pylori theory is very important .

•**Helicobacter pylori** is the major etiological factor in peptic ulcer disease (95% in duodenal and 80% in gastric ulcer).

Prostaglandins are protective in stomach  
It increases bicarbonate in mucous + blood flow and decreases HCL secretion




**Hydrochloric acid and pepsin** destroy gastric and duodenal mucosa.

**Decrease mucus and bicarbonate ion** secretions that protect mucosa

**Decrease Prostaglandins release** ( $\text{PGE}_2$  &  $\text{PGI}_2$ ) that protect mucosa by inhibiting acid secretion, increasing mucus and bicarbonate production and by enhancing mucosal blood flow. (NSAIDs)

Simply it is imbalance between Aggressive factors (Acid & Pepsin) and Defensive Factors (e.g. Prostaglandins)

Mucosal cytoprotective agents



## Etiology:

**H.pylori infection number 1**

- Alcohol
- Smoking
- Caffeine (increases gastric acid)
- Genetic factors ex:Blood type B
- Diet
- Hypersecretory states (Zollinger Ellison syndrome)
- Drugs (e.g.) NSAIDs  
(NSAIDs affect the kidney and the GIT) it increase gastrin >> increase HCL  
Also it decreases prostaglandins



## Zollinger Ellison syndrome

- Is characterized by excessive production of gastrin by gastrinoma of the pancreas or duodenum that stimulates parietal cells of the stomach to release excessive amounts of gastric acid.
- Gastrin produces:
  - Parietal cell hyperplasia (trophic factor).
  - Excessive gastric acid production.

A non-beta islet cell, gastrin-secreting tumor of the pancreas that stimulates the acid-secreting cells of the stomach to maximal activity, with consequent gastrointestinal mucosal ulceration.

Gastrinoma of the pancreas

Hyperplasia of the parietal cells

Increase HCL

hypergastrinemia

## Gastric secretions

1. HCl and intrinsic factor (Parietal cells).

2. Pepsinogens (Chief cells).

3. Mucus, bicarbonate (mucus-secreting cells).

(The mucus producing cells in the stomach help to form a protective lining to keep the digestive juices from digesting the stomach itself)

## Regulation of gastric secretions

**Parietal cells secrete acid in response to:**

1. Histamine (local hormone):  $H_2$  receptors

2. Gastrin (hormone):  $CCK_2$  receptors

3. Ach (neurotransmitter):  $M_3$  receptors

4. Proton pump ( $H^+ / K^+$  ATPase)

**N.B.  $CCK_2$  = cholecystinin receptors**




# Regulation of gastric secretions

Vagal supply of muscarinic receptor, Ach is the transmitter

Stimulation of H<sub>2</sub> receptor increase the gastric secretion

Stimulation of the CCK<sub>2</sub> receptor increase the gastric acid secretion



Stimulation of proton pump cause the pumping out the hydrogen ion in exchange with the potassium.

In treatment: we can block the final step (very effective)



# Treatment of peptic ulcer

**Eradication of *H. pylori* infections (first step very important)**

Otherwise the recurrence of ulcer increases due to increase the secretions

**Hyposecretory drugs:**

Proton pump inhibitors (most potent)

H<sub>2</sub> receptor blockers

Antimuscarinic drugs

They will **decrease gastric acid** secretion  
→ Promote healing & relieve pain.

**Protective measures:**

**Mucosal cytoprotective agents:**

Prostaglandin analogues

Prostaglandins alone has short duration of action, so we give Prostaglandin analogues

**Protective measures:**

**Neutralizing agents (antacids).**

## Mechanism of action

Acts by irreversible inhibition of proton pump (H<sup>+</sup>/ K<sup>+</sup> ATPase) that is responsible for final step in gastric acid secretion from the parietal cell.

The drugs are:

- Omeprazole
- Lansoprazole
- Pantoprazole
- Rabeprazole
- Esomeprazole
- Remember PPI >> Prazole (suffix)

## Pharmacodynamics

- They are the **most potent inhibitors** of acid secretion available today.
- Produce marked inhibition of basal & meal stimulated-acid secretion (90-98%).
- **Reduce** pepsin activity. (pepsin will be activated in the presence of HCL, so reduced gastric acid decrease the pepsin)
- Promote mucosal healing & decrease pain.
- Proton pump inhibitors heal **faster** the ulcers than H<sub>2</sub> blockers, and **have H. pylori inhibitory properties.** PPI one of the contents in H.pylori eradication therapy

## Pharmacokinetics

- All Given orally
- Are pro-drugs (activated in the body)
- rapidly absorbed from the intestine.  
(from the intestine to the bloodstream back to the stomach)
- Activated in the acidic medium of parietal cell canaliculi. (active form gives the action)
- **Inactivated** if at neutral pH.
- Should not combined with H<sub>2</sub> blockers or antacids.  
(cause those two groups will decrease the acidity in the parietal cells, so by that decreasing it's activity, H<sub>2</sub> blockers reduces the acidic medium requires for activation of PPIs)
- Have long duration of action (> 12 h-24 h).
- Once daily dose is sufficient
- Given 1 h before meal.
- Bioavailability is reduced by food.
- metabolized in the liver by Cyt-P450.
- **Dose reduction** is required in severe liver failure.

## USES

- Eradication of H. pylori (combined with antimicrobial drugs).
- Peptic ulcer ( 4-8 weeks) resistant to H<sub>2</sub> antagonists.  
  
(Firstly we use the H<sub>2</sub> blockers (especially moderate cases) ,if the patient is not responding we start the PPIs (expensive given in severe cases))
- Hypersecretory conditions as Zollinger Ellison syndrome (**drug of choice**).
- Reflux esophagitis.

## Adverse effects

- **Headache, diarrhea & abdominal pain.**
  - **Achlorhydria**  
(the production of the acid is reduced or absent, Low HCL)
  - **Hypergastrinaemia.**
  - **Gastric mucosal hyperplasia.**
    - **Increased bacterial flora.**
    - **increased risk of community-acquired respiratory infections & pneumonia.**
- Long term use:**
- **Vitamin B<sub>12</sub> deficiency**  
( due to the decrease in the level of gastric intrinsic factor)
  - **increased risk of hip fractures.**

PPI therapy leads to diminished acid secretion



Diminished D-cell release of somatostatin (body thinks that the acis is low)



consequent increased G-cell release of gastrin and hypergastrinemia.



This causes oxynitic cell hyperplasia (but the praietal cells are blocked, can't produce HCL)

Mechanism of action	Pharmacokinetics	pharmacological actions
<ul style="list-style-type: none"> <li>• They competitively and <b>reversibly</b> block H<sub>2</sub> receptors on the parietal cells.</li> <li>Used more than once per day</li> <li>- Cimetidine - Ranitidine</li> <li>- Famotidine - Nizatidine</li> </ul>	<ul style="list-style-type: none"> <li>• Good oral absorption</li> <li>• <b>Given before meals.</b></li> <li>• <b>Famotidine</b> is the most potent drug, so small doses are given</li> <li>• Exposed to first pass metabolism (except nizatidine that has 100 % bioavailability).</li> <li>• Duration of action (4-12 h).</li> <li>• *Metabolized by liver.</li> <li>• *Excreted mainly in urine.</li> <li>• ** be careful in case of liver or renal disorders)</li> <li>• Cross placenta &amp; excreted in milk (should not be given in pregnancy unless it is necessary).</li> </ul>	<ul style="list-style-type: none"> <li>• Reduce basal and food stimulated-acid secretion</li> <li>• <b>Block 90% of nocturnal acid secretion</b> (which depend largely on histamine) &amp; 60-70% of total 24 hr acid secretion. Therefore, it is better to be given <b>before night sleep.</b></li> <li>• Reduce pepsin activity.&gt;&gt; healing &gt;&gt; less pain</li> <li>• Promote mucosal healing &amp; decrease pain</li> <li>• <b>Reduce acid secretion stimulated by histamine, as well as by gastrin &amp; cholinergic drugs.</b></li> </ul>

## USES

- GERD (heartburn/ dyspepsia).
- Acute ulcer healing **in moderate & mild cases.**
- Duodenal Ulcer (6-8 weeks).
- Benign gastric ulcer (8-12 weeks).
- **In severe cases we use PPIs (proton pump inhibitors)**
- Zollinger Ellison Syndrome
- **Pre-anesthetic medication** (to prevent aspiration pneumonitis).
- Prevention of bleeding from stress-related gastritis.
- **Post-ulcer healing maintenance therapy.** (if the patient doesn't have H.pylori infection)
- Decrease the heartburn by NSAIDs
- PUD: effective in nocturnal acid suppression & ulcer healing in moderate cases

Use  
Famotidine  
better than  
Cimetidine  
cuz it  
requires  
high dose

## Adverse effects

- GIT disturbances (Nausea & Vomiting).
- CNS effects: Headache – confusion (elderly **they have confusion commonly**, hepatic dysfunction, renal dysfunction).
- Bradycardia and hypotension (rapid I.V.)
- CYT-P450 inhibition (**Only Cimetidine**) decrease metabolism of warfarin, phenytoin, benzodiazepines.
- **Endocrine effects (Only Cimetidine)**
  - Galactorrhea (Hyperprolactinemia)
  - Antiandrogenic actions (gynecomastia –impotence) *due to inhibition of dihydrotestosterone binding to androgen receptors.*
  - **Dose vary according to patient condition**

## Precautions

Dose reduction of H<sub>2</sub> RAs in severe renal or hepatic failure and elderly.

	CIMETIDINE	RANITIDINE	FAMOTIDINE	NIZATIDINE
<b>Efficacy</b>	+++	++ +	+++	+++
<b>Potency</b>	+ <i>Less potent 2times/day</i>	++	+++	++
<b>Dose</b>	400 mg bid	150 mg bid	20mg bid	150 mg bid
<b>Route</b>	orally, IV	orally, IV	orally, IV	orally
<b>T 1/2</b>	short (2 h)	longer (3h)	longer (3h)	shortest (1
<b>Duration</b>	5-6 h	10 h	12 h	11 h
<b>CYT P 450</b>	++	-	-	-
<b>Antiandrogenic</b>	++	-	-	-
<b>Drug interactions</b>	many	No	No	No

The doctor focused on cimetidine

Not important to  
memorize dose



## Antacids

Alkaline substance neutralize acids

These drugs are mainly **inorganic salts**  
e.g.:  $\text{NaHCO}_3$ ;  $\text{CaCO}_3$ ;  $\text{Al(OH)}_3$ ;  $\text{Mg(OH)}_2$

- acts by direct chemical neutralization of HCL and as a result may decrease pepsin activity.

- used to relief pain of peptic ulcer & for dyspepsia. (without healing), it may rebounds pain by increasing HCL

- All antacids ↓ absorption of some drugs as

tetracycline, fluoroquinolones, iron.

**$\text{NaHCO}_3$** : Systemic alkalosis;  **$\text{CaCO}_3$** : milk(Ca) alkali syndrome(basic medium) (hypercalcemia lead to renal stones>, renal failure hypercalcemia)

**$\text{Al(OH)}_3$** : constipation;  **$\text{Mg(OH)}_2$** : Diarrhea

\*\*Give both to balance

## Misoprostol

- Prostaglandin analogues (PGE1)**
- ↓ HCL secretion.
- ↑ protective measures (↑ mucous/bicarbonate & gastric mucosal blood flow).
- Orally, must be taken 3-4 times/day, has short duration of action.
- Used for NSAIDS-induced peptic ulcer by lowering prostaglandins

### Adverse effects:

- Abdominal cramps; diarrhea
- Uterine contraction (dysmenorrhea or abortion);
- Vaginal bleeding. → dont give in pregnancy



- All PUD patients must be evaluated for *H. pylori*.
- Patients with *H. pylori* should be treated.
- Eradication is important to prevent recurrence of ulcer.
  
- A combination of antibiotics and acid-reducing medicines is the most effective treatment.
  - PPIs or H<sub>2</sub> receptor blockers
  - Antibiotics
    - Clarithromycin
    - Tetracycline or amoxicillin
    - Metronidazole if patient allergic to penicillin.
  - Bismuth subsalicylate.
  - NO TREATMENT OF PUD WITHOUT TREATING H.PYLORI

### Triple therapy (First-line therapy):

1. Proton pump inhibitors (PPIs)
2. Clarithromycin **effective**
3. Amoxicillin (**metronidazole** is substituted for amoxicillin in patients allergic to penicillin).

### Quadruple therapy (bismuth-based regimen)

1. Proton pump inhibitors (PPIs)
2. Bismuth subsalicylate (bismuth whatever the salt is)
3. Metronidazole
4. Tetracycline, **Clarithromycin is more effective**



Could be changed

First we use Triple therapy for 2\_3 weeks then >> test blood for H.pylori ,if it's (-) >> treat ulcer by hyposecretory drugs  
If it's (+) >> Quadruple therapy

- Test for *H. pylori* before starting the therapy.
- Complete *H. pylori* eradication is required to prevent relapse.
- Acid-reducing medications are prescribed in case of PUD **without** *H. pylori* infections.
- Acid-reducing medications for PUD include:
  - H<sub>2</sub>RAs (H<sub>2</sub> receptors antagonists).
  - PPI's should be used for acute therapy only if H<sub>2</sub>RAs fail or cannot be used, or as part of treatment for *H. pylori*.
- **PUD with *H. pylori* infections can be treated with**
- **Triple therapy** PPI's + clarithromycin + amoxicillin
- **Quadruple therapy**  
PPI's + Bismuth + Metronidazole + tetracycline

Summary from 431teamwork (thanks to Wael al saleh)



## Drugs used in Peptic Ulcer

Drug	MOA	Pharmacokinetics	ADRs
<p><b>1-Anti-acids:</b> These drugs are mainly inorganic salts (e.g.: <math>\text{NaHCO}_3</math>; <math>\text{CaCO}_3</math>; most commonly used <math>\text{Al}(\text{OH})_3</math>; <math>\text{Mg}(\text{OH})_2</math>)</p>	<p>Antagonize <b>acid</b>; Also, Indirectly may decrease <b>pepsin</b> activity</p>		<p>constipation (<b>from Al</b>), diarrhea (<b>from Mg</b>), hypophosphatemia...others <b>note:</b> preparations that combine both Al and Mg hydroxides are used as their actions will cancel each other.</p>
<p><b>2- H<sub>2</sub> -receptor antagonists:</b> e.g. <b>Cimetidine (prototype)</b> <b>most clinically use : Ranitidine (Zantac);</b> Famotidine (most potent) ; Nizatidine <b>Used In :</b></p> <ul style="list-style-type: none"> <li>• GERD (gastroesophageal reflux disease), (heartburn/ dyspepsia).</li> <li>• PUD(peptic ulcer disease): <b>effective in nocturnal acid suppression &amp; ulcer healing</b> in moderate cases</li> <li>• Prevention of bleeding from stress-related gastritis.</li> <li>• Decrease the heartburn by NSAIDs.</li> <li>• Zollinger Ellison Syndrome (large doses).</li> </ul>	<p>They competitively &amp; reversibly bind to H<sub>2</sub>-receptors on the parietal cells, thus decreasing the production of acid by these cells. <b>* Highly selective on H<sub>2</sub> receptors</b></p> <p><b>Pharmacological Actions :</b> 1-Reduce basal &amp; food-stimulated gastric acid secretion. 2-Reduce acid secretion stimulated by histamine, as well as by gastrin &amp; cholinergic drugs. 3-Reduce pepsin activity. Block <b>90% of nocturnal acid secretion</b> (which depend largely on <b>histamine</b>) ;Therefore, it is better to be given before night sleep</p>	<p>-Good &amp; rapid oral absorption -Plasma half life (1-4 hr). -Duration (4-12 h) , given twice a day -First pass metabolism (50%, Except <b>Nizatidine 100 % bioavailability</b>). -Given before meals (all PU drugs are given on empty stomach) -Clearance by hepatic metabolism, glomerular filtration &amp; renal tubular secretion. -Dose reduction is required in patients with moderate-severe renal (or severe hepatic) insufficiency. -50% clearance decline in elderly -Cross placenta &amp; excreted in milk. <b>* Ranitidine is more potent; 150 mg can give the therapeutic effect, compared to 400 mg for cimetidine.</b></p>	<p>-CNS effects: Headache,confusion, hallucination &amp; agitation due to IV H<sub>2</sub> antagonist (<b>more with cimetidine</b> in ICU especially (elderly –renal or hepatic dysfunction)) but not with Ranitidine. <b>-Endocrine effects (For Only Cimetidine) :</b></p> <ul style="list-style-type: none"> <li>• -increases in serum prolactin (Galactorrhea in women).</li> <li>• -Inhibits binding of dihydro-testosterone to androgen receptors (gynecomasteia –impotence).</li> </ul> <p>-All cross placenta &amp; breast milk, should not be given in pregnancy unless it is necessary. <b>ranitidine</b> can be given to pregnant woman. - Inhibition of C<sub>ty</sub> p450 by Cimetidine. (potential toxicity from other drugs administered concomitantly). -Leukopena and thrombocytopenia and headache with <b>ranitidine</b>(rare). -GIT disturbances (Nausea &amp; Vomiting) -Bradycardia &amp; hypotension (rapid I.V)</p>
<p><b>3- Proton pump inhibitors.:</b> e.g.: <b>Omeprazole ; Lansoprazole ; Pantoprazole ; Rapprazole</b> <b>Used In :</b></p> <ul style="list-style-type: none"> <li>• Gastric and duodenal ulcer (H.pylori Eradication)</li> <li>• Zollinger–Ellison syndrome. (1st )</li> <li>• GERD</li> <li>• NSAIDs associated ulcer</li> <li>• prevention of bleeding from stress-related gastritis.</li> <li>• PUD ( 4-8 weeks); faster &amp; long- lasting ulcer relief.</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Irreversible inhibition of proton pump (H<sup>+</sup>/ K<sup>+</sup> ATPase) that is responsible for final step in gastric acid secretion from the parietal cells.</b></li> <li>• 24 hr inhibition of basal &amp; meal stimulated-acid secretion (90-98%).</li> </ul>	<p>-They are prodrugs. -All are taken orally. -Esomeprazole &amp; pantoprazole are also available in IV formulation. Give to those who can't swallow because of bleeding. -All are given as enteric coated tablets/ capsules –To protect them from destruction by acidity in gastric lumen -They are rapidly absorbed from the intestine &amp; converted to active form. -PPIs have plasma half life of 1.5 h <b>-Long duration of action (&gt; 12 h-24 h)</b>, because of the irreversible inactivation of the proton pump. -Once daily dose is sufficient -Bioavailability is reduced by food (50%). -Given 1 h before meal; on empty stomach. -Are metabolized in the liver <b>by CytP450</b>. So dose reduction is required in severe liver failure. <b>They are more potent than H<sub>2</sub> antagonists.</b></p>	<p>-Headache. -Diarrhea. -Nausea. -decreased gastric acid secretion lead to <b>hypergastrinemia</b> mucosal hyperplasia. <b>prolonged acid suppression leads to:</b></p> <ul style="list-style-type: none"> <li>* subnormal B12 levels (because acid is required for its absorption).</li> <li>* risk of hip fracture if taking PPIs over a long period.(PPIs may reduce calcium absorption or inhibit osteoclast function).</li> <li>* colonization &amp; infection of the stomach &amp; intestine from ingested bacteria; increased risk of both community-acquired respiratory infections &amp; nosocomial pneumonia.</li> </ul> <p><b>Note: Despite all the above PPIs are very save drugs.</b></p>



## How Gastroesophageal Reflux could be managed?


- Decrease gastric acidity (H2 blockers or PPIs).
- Increase tone of LOS (lower esophageal sphincter) and increase gastric emptying by Metoclopramide.
- Avoid drugs or foods that trigger GERD. (caffeine, alcohol, smoking).
- Avoid sleeping after meal and try to use two to three pillows.

## Eradication Of H. Pylori

- Is a bacteria that causes chronic inflammation of the inner lining of the stomach.
- Duodenal ulcer -Gastric ulcer.
- Produces enzymes (tissue damage).
- Risk factor for gastric cancer.
- Eradication is important to prevent recurrence of ulcer.
- The best treatment regimen: **Triple therapy (10-14 days).**( PPIs bid ,Clarithromycin, Amoxicillin)

## Summary:

- Most common cause (agent) in peptic ulcer **H. Pylori infection**. Others: smoking, caffeine, drugs...etc.
- Objective of treatment: (prevention of further ulcer recurring, Relieve pain; healing of ulcer).
- Best approach in treatment is the **eradication of H. Pylori**.
- Treatment available: antacids, H2-antagonist, and **PPI**.
- Antacids give **symptomatic relief**, Al and Mg hydroxides most commonly used.
- H2-antagonist: Ranitidine(**more potent**), cimetidine( **enzyme inhibitor +anti-androgenic**)
- All cross placenta.
- PPIs **irreversibly** inhibit proton pump (H/K ATPase).
- Do not use PPIs concomitantly with H2-antagonist.
- PPI are **more potent** than H2-antagonist.
- PPI side effects: diarrhea, nausea + **hypergastrinemia** + **B12 deficiency** + risk of hip fracture.
- PPIs are **pro-drugs**.
- One of the ways to manage Gastroesophageal reflux is to avoid sleeping after meal and try to use two to three pillows.
- Eradication of H. Pylori **by triple therapy for (10-14) days**. (chart above).
- Clinical uses of IPP include: **Gastric and duodenal ulcer (H.pylori Eradication), Zollinger Elison syndrome. GERD, NSAIDs.**
- Clinical uses of H2-antagonist: PUD ( **effective in nocturnal acid suppression**), prevention of bleeding form stress-related gastritis.



1. which one of these drug is a prodrug ?

- a. Famotidine    b.Nizatidine    c.Omeprazole

2. which one of these drug is first choice for Zollinger Ellison Syndrome ?

- a.Cimetidine    b.Raprazole    c.Ranitidine

3. which one of these drug we can't use it with warfarin?

- a.Nizatidine    b.Cimetidine    c.Ranitidine

1-C    2-B    3-B



# PHARMACOLOGY TEAM



---

**Pharmacology leaders:  
Tuqa Alkaff & Abullah Alanzi**

**Email:  
[pharmacologyteam1@gmail.com](mailto:pharmacologyteam1@gmail.com)**